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Cyclophosphamide therapy for lupus nephritis: Poor renal survival in
black Americans. Intravenous cyclophosphamide is widely used to treat
severe lupus nephritis. Yet interpretation of the literature is limited by the
small number of patients evaluated with varied renal histology. We
analyzed the renal Outcome of cyclophosphamide therapy for diffuse
proliferative lupus glomerulonephritis in a cohort of 89 patients from the
Glomerular Disease Collaborative Network. Statistical analysis included
Wilcoxon rank sum tests or continuity-adjusted chi-square for compari-
sons between groups. Kaplan-Meier survival function estimates were
calculated for renal survival curves. Cox's proportional hazards models
were employed for multivariate evaluation. The renal survival rate de-
clined yearly from 89%, to 86%, 81%, 75%, and 71% at year 5. Renal
survival was significantly worse in blacks compared with white patients.
Among white patients 95% retained renal function at year 5 whereas black
patients showed a progressive yearly decline from 85% at year 1, to 79%,
72%, 62%, and 58% at year 5. Racial differences in renal outcome were
independent of age, duration of lupus, histoiy of hypertension, hyperten-
sion control during therapy, and activity or chronicity indices on renal
biopsy. The factors that predispose black patients to more aggressive and
treatment-resistant lupus nephritis are not apparent.
The treatment of patients with systemic lupus erythematosus
who have diffuse proliferative glomerulonephritis (SLE-DPGN)
remains controversial. Clinical trials of intermittent intravenous
cyclophosphamide therapy demonstrate greater long-term renal
but not overall survival compared with corticosteroids [1—4].
Longer duration of cyclophosphamide therapy has recently been
shown to be associated with less frequent relapse of active
nephritis and better renal outcome [4]. Interpretation of the
outcomes of these studies has been limited by several important
factors. Despite the greater frequency [5—7] and severity [8—12] of
systemic lupus erythematosus (SLE) in American blacks, clinical
trials have included a majority of white patients or do not specify
race [1—4]. Study designs have included patients with varying
histologic lesions, although recent studies confirm prognostic
implications of renal biopsy staging [13—15]. Previous studies have
included patients with prolonged duration of nephritis prior to
study entry, limited study entry by excluding patients with severely
impaired renal function [1, 4], or required a minimum therapeutic
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compliance for study inclusion [1]. No previous studies have
evaluated renal outcome of cyclophosphamide therapy in commu-
nity settings.
We undertook this study to assess renal outcomes among
patients with SLE-DPGN followed by physicians within the
Glomerular Disease Collaborative Network (GDCN). We wished
to define the outcome of the clinical decision to employ cyclo-
phosphamide therapy for SLE-DPGN. We report important
differences in SLE-DPGN renal outcomes in this majority black
and community practice-based population.
This protocol was approved by the Committee on the Protec-
tion of the Rights of Human Subjects at the University of North
Carolina School of Medicine.
Methods
Selection of subjects
Patients with a renal biopsy diagnosis of SLE-DPGN from
within the Glomerular Disease Collaborative Network (GDCN)
were eligible for inclusion in this study. The GDCN, organized in
1984, has grown to include over 200 nephrologists primarily in
private practice throughout the southeastern United States (Ap-
pendix). In 1985, the GDCN established registries for glomerular
diseases, including SLE-DPGN, to allow prospective observa-
tional studies. Patients were enrolled into the registry at the time
of their renal biopsy diagnosis (October 1985 to July 1995).
Clinical and laboratory data were gathered prospectively.
Once eligibility by renal biopsy diagnosis was established,
medical record information from participating nephrologists and
all treating physicians from the time of the patient's onset of lupus
were retrospectively examined to establish that patients fulfilled
four or more criteria from the 1982 ACR revised criteria for
classification of systemic lupus etythematosus [16]. Documenta-
tion of treatment or intention to treat with intravenous cyclophos-
phamide was required for study entry.
In 1985, the GDCN adopted a modified version of the NIH
protocol for lupus nephritis: intravenous cyclophosphamide given
once a month for six months at a dose of 0.5 to 1.0 gram per meter
square adjusted to the patient's nadir white blood cell count.
Further quarterly infusions of intravenous cyclophosphamide
were based on the renal response of the individual patient. Oral
prednisone was recommended at a starting dose of 60 milligrams
per day for two months, and tapered as required for individual
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patients. In 1989, the GDCN began recommending intravenous
methyiprednisolone at a dose of 7 milligrams per kilogram per day
for three days at the time of diagnosis based on reports of efficacy
[17—23]. Patients treated with other immunosuppressive regimens
were excluded from this analysis.
Renal patholo
Each renal biopsy specimen was evaluated by light, immuno-
fluorescence and electron microscopy by a single nephropatholo-
gist (JCJ). Specimens were required to have a minimum of 10
glomeruli for classifying the glomerulonephritis by light micros-
copy. Lupus glomerulonephritis was categorized based on the
recommendations of the World Health Organization (WHO), and
only subjects with Class IV, diffuse proliferative lupus glomerulo-
nephritis were included [241.
An overall activity score and chronicity score were calculated by
the method described [25]. Each individual pathology component
(on a scale of 0 to 4) was tested for its impact on renal survival.
Additionally, the sum of the activity and chronicity scores was
tested. The following pathologic features were scored on a scale of
0 to 4+ (0 = none, I = mild, 2 = moderate, 3 = moderately
severe, 4 = severe: glomerular hypercellularity, polymorphonu-
clear and interstitial leukocytes, necrosis, crescents, capillary wall
thickening, hyaline thrombi, and sclerosis; tubular atrophy; inter-
stitial sclerosis; arterial sclerosis; and glomerular intensity of
immunofluorescence staining for IgG, IgA, 1gM, C3, Clq, kappa
light chains and lambda light chains.
Statistical analysis and definitions
Renal survival was the primary outcome of interest, with time to
end-stage renal disease (ESRD) requiring chronic dialysis or renal
transplantation as an endpoint. Patients not reaching an endpoint
were censored at the date of their last follow-up visit or their
death, if death occurred prior to reaching ESRD. The start date
was the date of the first renal biopsy with a diagnosis of SLE-
DPGN.
Kaplan-Meier survival function estimates were calculated for
renal survival of the group as a whole and for exploratory
univariate analysis of potential influential variables on survival
[261. Log rank tests were used for comparison of survival estimates
between groups. Evaluation of the impact of continuous variables
on renal survival was done separately comparing above and below
the first quartile, median and third quartile. Other specific inter-
vals of clinical interest were also evaluated. The median is
reported unless statistical significance for another cut-off was
found, or clinical significance at another cut-off was anticipated to
be important.
Comparisons of demographics, baseline characteristics, and
treatment between groups with different renal survival estimates
were done using Wilcoxon rank sum tests or continuity adjusted
chi-square for continuous and categorical data, respectively.
Cox's proportional hazards models were used for multivariate
analysis of renal survival. Visual analysis of residuals was done to
assess goodness of fit for final models. The log of the negative log
for survival by each covariate was viewed to determine if the
proportional hazards assumption was valid [271. Interaction terms
were not tested due to the limited sample size (N = 89) and the
number of renal outcomes (N = 19). The pre-planned require-
ments for keeping variables in the final model included; statistical
significance with a P value less than or equal to 0.05 or a change
in the risk ratio of interest of more than 25%. As variables were
entered into the model by the above criteria, models were
compared with the log likelihood chi-square goodness of fit test to
determine if the added variable added to the overall prediction of
outcome. This study had statistical power of 0.80 to detect
minimum risk ratios of 2.3.
Luptis duration was defined as the time from a patient's first
documented lupus diagnosis to the renal biopsy diagnosis of
SLE-DPGN. Clinical manifestations of lupus were recorded as
present or absent for each patient at any time during the
documented course of the patient's illness. Information recorded
for each patient consisted of clinical variables including serial
blood pressure measurements, SLE manifestations, initiation of
dialysis or transplantation, mortality, adverse treatment effects,
and 41 laboratory variables. Medication history included dose and
duration of corticosteroids, intravenous cyclophosphamide and
antihypertensive therapy.
Uncontrolled hypertension was defined as a systolic pressure
greater than 140 mm Hg and/or a diastolic pressure greater than
90 mm Hg, with or without antihypertensive therapy. Uncon-
trolled hypertension during therapy was defined as having pres-
sures as defined above on two or more office visits more than a
month apart during the 12 months following renal biopsy. Mea-
surement of blood pressure was performed as a routine office
procedure with a single measure obtained per visit. Blood pres-
sure measurements recorded in the medical record for visits
within 2 weeks of the entry, 3, 6, and 12 month visits following
renal biopsy were utilized.
Results
A total of 122 patients were eligible by renal biopsy diagnosis.
Twenty-five were not offered intravenous cyclophosphamide ther-
apy; information was not available on five patients, and three
additional patients lacked sufficient documentation of lupus cri-
teria.
The demographics and entry characteristics of the 89 patients
eligible for this study are shown in Table 1. There were 51 black
patients, 38 white patients, and 1 Asian/white patient. For the
purposes of this analysis, the Asian/white patient is grouped with
the white patients, making two groups; black and non-black
patients. Forty-nine patients were evaluated and treated in com-
munity nephrology practices. The clinical manifestations of SLE
for patients are shown in Table 2. Photosensitivity was more
common in non-black patients.
A majority of patients underwent renal biopsy with entry serum
creatinine values within the normal range (Table 1). However, ten
of the 89 patients required dialysis within 30 days of their renal
biopsy. Of the seven patients who recovered renal function, five
did so within 2.5 months, and the remaining two patients at 8 and
10 months of starting dialysis. Two of the seven patients receiving
temporary dialysis (both for less than 1 month) at the time of
SLE-DPGN diagnosis progressed to ESRD at 12 and 68 months
after discontinuing acute dialytic therapy.
Only three deaths (2 black patients, 1 non-black) occurred in
patients prior to development of ESRD; therefore, overall patient
survival was not calculated. Two of the three deaths could be
attributed to therapy: one patient exsanguinated two months after
renal biopsy from a bleeding duodenal ulcer during high dose
corticosteroid therapy, and the second patient died of sepsis with
normal renal function 10 months after renal biopsy. The third
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Table 1. Summary statistics of the 89 diffuse proliferative lupus
glomerulonephritis patients
Variable N (%) Median (range)
Female 77 (86.5)
Black 51(57.0)
Age at biopsy years 33 (8 to 69)
SLE duration months 20 (0 to 24 years)
Serum creatinine mg/dl 1.4 (0.2 to 9.6)
Cumulative IV cyclophosphamide 6.3 (0.0 to 42.7)
grams
Duration of IV cyclophosphamide 10 (0 to 43)
months
Systolic blood pressure at biopsy 142 (88 to 200)
mm Hg
Diastolic blood pressure at biopsy 92 (55 to 132)
mm Hg
Uncontrolled hypertension at 49 (55)
biopsy
Uncontrolled hypertension during 28 (31)
therapy
Treated with methylprednisolone 45 (50.6)
Lupus manifestations Blacks Non-blacks P value
Malar rash 19 (46%) 25 (71%) 0.06
Discoid rash 1(0.02%) 2 (7%) 0.59
Photosensitivity 9 (18%) 16 (57%) 0.02
Mucosal ulcers 10 (20%) 14 (37%) 0.07
Arthritis 28 (55%) 26 (68%) 0.28
Serositis 22 (43%) 17 (45%) 0.88
Neurologic disorder 8(16%) 4(11%) 0.70
Hematologic disorder 31(61%) 17 (45%) 0.20
Immunologic disorder 35 (69%) 26 (68%) 0.98
Antinuclear antibody 50 (98%) 34 (89%) 0.20
death resulted from unknown causes at home (with normal renal
function 1 month prior to death) five years after renal biopsy.
Eight patients expired during the course of treatment for ESRD,
Fifteen patients were lost to follow-up during the course of the
study (9 black patients with a median observation of 36.4 months,
range 0.13 to 92 months; 6 non-black patients median observation
19.8 months, range 1.16 to 32 months following renal biopsy).
Renal survival
Nineteen patients reached end-stage renal disease requiring
chronic dialysis (N 17) or transplantation (N =2). The five-year
renal survival curve is shown in Figure 1. Renal survival for the
cohort overall was 89% at year 1, 86% at year 2, 81% at year 3,
75% at year 4, and 71% at year 5. The shape of the curve within
the first year of the study period was influenced by a subset of
patients (N 9) who progressed to renal failure within 12 months
of biopsy.
Univariate analysis of renal survival was explored for potential
demographic and clinical predictors of renal survival including
age, race, sex, SLE duration, entry serum creatinine level, the
presence of uncontrolled hypertension during therapy and treat-
ment with intravenous methylprednisolone. None of the variables,
with the exception of race which is discussed below, had a
statistically significant impact on renal survival (Table 3).
In this restricted WHO Class IV population, we found no
0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 4.5 5.0
Years from renal biopsy
Fig. 1. Kaplan-Meier survival estimates for renal survival out to 5 years in 89
patients with diJJhse proliferative lupus glomerulonphritis. Yearly survival
estimates are: 89% at 1 year, 86% at 2 years, 81% at 3 years, 75% at 4
years, and 71% at 5 years.
independent effects of individual histologic variables on renal
survival as shown in Table 4. The combination of activity and
chronicity (sum) was an important predictor for ESRD, with
patients in the highest quartile (combined score >14) being more
likely to progress (Table 4).
Renal survival by race
The renal survival estimates were significantly worse for blacks
than for non-blacks (P = 0.02; Table 3; Fig. 2). Seventeen of
nineteen patients who reached ESRD were black. Eight of the
seventeen black patients reached ESRD within 8 months from
renal biopsy during intensive intravenous cyclophosphamide and
corticosteroid therapy. Blacks also had a continual decrease in
renal survival out to five years. In contrast, only two of 38
non-black patients reached ESRD, leaving a continuous renal
survival of 95.5% in this group over five years (Fig. 2).
Comparison of baseline demographic and clinical variables
between blacks and non-blacks are shown in Table 5. The black
patients were significantly younger but no other baseline variables,
including sex, duration of lupus, entry serum creatinine values,
and renal biopsy scores for activity or chronicity, were different
between the racial groups. The median duration of SLE prior to
renal biopsy appeared shorter for blacks (13 months) than for
non-blacks (33 months). There was a clustering of black patients
with a lupus duration of less than six months (N = 21); therefore,
the univariate impact of duration of lupus before and after this
point on renal survival was evaluated but did not reach statistical
significance (P = 0.14).
Blacks (N = 7) were no more likely than non-blacks (N = 3) to
receive dialysis within 30 days of their renal biopsy (P = 0.60).
Three black patients never recovered renal function, despite
institution of cyclophosphamide therapy. Of the seven patients
who recovered renal function, two eventually reached chronic
dialysis after 12 and 68 months of follow-up. The five remaining
patients (3 black, 2 non-black) recovered function and remained
off chronic dialysis during the study (15, 18,38,45 and 92 months).
When controlling for other variables the impact of race remains
significant (Table 3). Among black patients alone, none of the
pathology variables predicted development of ESRD (data not
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Table 2. Lupus disease manifestations by race among 89 patients with
diffuse proliferative glomerulonephritis
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_________
Pathology variables
(range of possible values)
Activity (0—24)
Chronicity (0—12)
Activity and chronicity
IgG (0—4)
IgA (0—4)
1gM (0—4)
C3 (0—4)
_____________
Clq (0—4)
Kappa light chains
(0—4)
Lambda light chains
(0—4)
SEP (present vs. absent)
TIB (present vs. absent)
Arterial sclerosis (0—4)
Glomerular necrosis
(0—4)
Glomerular crescents
(0—4)
Increased glomerular
cellularity (0—4)
Sclerotic crescents
(0—4)
Polymorphonuclear
Icukocytes (0—4)
Interstitial leukocytes
(0—4)
Glomerular sclerosis
(0—4)
Interstitial sclerosis
(0—4)
Tubular atrophy (0—4)
Table 3. Evaluation of the impact of variables on renal survival Table 4. Evaluation of the impact of pathology variables on renal
Outcome
Univariate Multivariate
conditional conditional
risk ratio risk ratio
Variable Median (P value) (P va1ue)'
Female 1.4 (0.61) 1.5 (0.75)
Black 5.9 (0.02) 11.1 (0.03)
Age at biopsy years 33 0.9 (0.89) 1.0 (0.90)
SLE duration months 21 2.6 (0.06) 4.6 (0.07)
Serum creatinine mg/dl 1.4 1.9 (0.19) 0.6 (0.60)
Uncontrolled hypertension 2.1 (0.23) 1.5 (0.64)
during therapy
Treated with 2.5 (0.09) 1.4 (0.66)
methylprednisolone
Multivariate
conditional
risk ratio
(P value)c
1.1 (0.84)
1.2 (0.75)
7.5 (0.02)
1.2 (0.77)
Univariate
conditional
risk ratio
Median (P value)a
___________
8.0 2.0 (0.17)
2.5 2.7 (0.06)
2.4 (0.005)
3.0 2.2 (0.13)
1.0 1.0 (0.97)
1.5 1.3 (0.56)
3.0 1.0 (0.99)
3.0 1.3 (0.62)
2.5 1.5 (0.35)
2.5 1.3 (0.60)
n/a 1.0 (0.98)
n/a 1.3 (0.65)
0.5 2.3 (0.11)
1.0 2.2 (0.15)
0.5 2.1 (0.11)
2.5 0.7 (0.56)
0.0 1.1 (0.84)
0.0 1.4 (0.53)
1.0 1.7 (0.35)
0.5 1.0 (0.97)
2.1 (0.15) 1.0 (0.98)
1.7 (0.33)
electron dense deposits; TIB,
2.3 (0.11)
2.0 (0.24)
1.6 (0.37)
From the Wald chi-square test, testing if the conditional risk ratio is
equivalent to 1.00
h Each variable tested while controlling all others in the table and
activity and chronicity
shown). Evaluation of the impact of variables on renal survival in
black patients alone is shown in Table 6. Shorter duration of SLE
prior to development of nephritis was associated with greater risk
of progression to ESRD.
Renal survival based on ently serum creatinine
Entry serum creatinine was within the normal range (1.3 mg/dl)
for nine of the 19 patients who progressed to end-stage renal
disease (8 black, 1 non-black). It was 1.5 to 3.0 mg/dl in four
patients (3 black, 1 non-black), 3.0 to 5.0 mg/dl in two black
patients, and 5.0 to 9.6 in three black patients. Exploration of the
impact of the entry serum creatinine was performed to determine
whether there was a point beyond which there was no recovery of
renal function. Without controlling for other factors, patients with
an entry serum creatinine greater than or equal to 3.0 mg/dl were
more likely to reach end-stage renal disease (P = 0.05) compared
to those with serum creatinine less than 3.0 mg/dl. This value
should he viewed with caution, however, because the comparison
is based on eight patients with serum creatinine values greater
than or equal to 3.0 mg/dl. Notably, five patients with serum
creatinine greater than or equal to 3.0 mg/dl maintained renal
function throughout the five-year study period.
Impact of blood pressure control
There were no differences between blacks and non-blacks in
systolic or diastolic blood pressure at the time of diagnosis, nor in
the percent of subjects within each race who had uncontrolled
blood pressure during the 12 months following renal biopsy.
Antihypertensive agents prescribed for blood pressure control
were similar between blacks and non-blacks. Of patients receiving
antihypertensive agents, eight patients received a single drug with
the remaining patients evenly divided by race between combina-
tion therapy groups receiving two agents or more than two drugs.
The most commonly prescribed drugs were diuretics (46 patients)
and calcium channel blockers (35 patients). Angiotensin convert-
ing enzyme inhibitors were rarely prescribed (8 patients), presum-
ably reflecting concern for increased risk of agranulocytosis and
angioedema in this population.
1.0
1.0
Abbreviations are: SEP, subepithelial
endothelial tubuloreticular inclusions; SEN, subendothelial electron dense
deposits (not evaluated because only 3 patients had presence of SEN).
a From the Wald chi-square test, testing if the conditional risk ratio is
equivalent to 1.00
"Each pathology variable tested individually while controlling for race
and duration of lupus (above and below the median, 21 months)
Race remained statistically significant (P < 0.05) in all models
d The value for the highest quartile and associated P values are reported
Effect of therapy
The percentage of blacks versus non-blacks receiving bolus
methyiprednisolone therapy at the time of SLE-DPGN diagnosis
was not different. All patients received concurrent corticosteroid
therapy, and no differences were seen in the tapering schedule of
blacks and non-blacks. Corticosteroid therapy was maintained for
greater than 12 months after renal biopsy in the majority of
patients.
The median cumulative intravenous cyclophosphamide dose
was less for blacks than for non-blacks. This was not unexpected,
considering more blacks reached end-stage renal disease during
the six month course of intravenous cyclophosphamide. A similar,
although not statistically significant, difference was seen in the
median duration of treatment with intravenous cyclophosphamide
between blacks (8 months) as compared to non-blacks (11
months). No differences between races were found in dose or
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Table 5. Comparison between blacks and non-blacks
Variable
Non-blacks
(N=38)
median"
Blacks
(N=51)
median P value"
Male/female ratio 6/32 7/44 0.72
Age at biopsy 36 27 0.04
SLE duration months 33 13 0.20
Serum creatinine mg/dl 1.3 1.4 0.52
Cumulative IV cyclophosphamide 7.8 6.0 0.03
dose grams
Duration of IV 11 8 0.13
cyclophosphamide months
Blood pressure at biopsy mm Hg 143/91 146/94 0.64/0.89
Uncontrolled hypertension at 58% 53% 0.80
biopsy
Uncontrolled hypertension during 32% 30% 0.85
therapy
Treated with methylprednisolone 47% 56% 0.19
Chronicity (0—12) 2.0 3.0 0.16
Activity (0—20) 7.0 9.0 0.14
Activity and chronicity 9.8 11.5 0.11
a Median unless otherwise stated as ratio or percent
b Wilcoxon Rank Sum test for continuous variables, continuity-adjusted
chi-square for categorical variables
duration of therapy in subjects who did not progress to ESRD
within six months.
A total of 19 patients (16 black, 3 non-black) received less than
six doses of cyclophosphamide. In nine patients (7 black, 2
non-black) cyclophosphamide was discontinued with the develop-
ment of ESRD. Seven of these patients (5 black, 2 non-black)
began chronic dialysis less than six months after biopsy. Two black
patients refused therapy; neither had reached renal endpoint at 38
and 39 months following renal biopsy. Two black patients were
noncompliant with therapy; neither had reached ESRD at 48 and
72 months after renal biopsy. Cyclophosphamide therapy was
discontinued in four patients (3 black, 1 non-black) due to
recurrent infections. None of the black patients had reached an
endpoint at 108, 88, and 32 months after biopsy; the non-black
Adverse effects of therapy
Infections were common among patients receiving immunosup-
pressive therapy. Herpes zoster developed in 12 patients (7 black,
5 non-black). Nine patients (6 black, 3 non-black) developed
sepsis during therapy, with repeated episodes in four patients (3
black, 1 non-black). Fungal infections occurred in four patients (3
black, I non-black). Five patients (4 black, 1 nonblack) developed
avascular necrosis of one or both femoral heads. Two pregnancies
occurred during cyclophosphamide therapy. Premature ovarian
failure was documented in five women. One patient each devel-
oped the syndrome of inappropriate secretion of antidiuretic
hormone, an osteoporotic fracture and steroid psychosis. Hemor-
rhagic cystitis did not occur. Overall complications of renal biopsy
were rare, however, one patient required nephrectomy for uncon-
trolled bleeding following biopsy.
Discussion
Intravenous cyclophosphamide has become the standard of
care for treating severe lupus nephritis despite few clinical trials
documenting efficacy. Cyclophosphamide therapy is associated
with a host of potentially severe toxicities including bone marrow
suppression, hemorrhagic cystitis, increased risks of infection,
future malignancies, and premature ovarian failure [28]. Previous
studies note prolonged renal but not overall survival with this
therapy [1], prompting continued intense debate as to the optimal
therapy for severe lupus nephritis. We define the outcome of a
unique population of patients with well-defined SLE-DPGN
including a majority of black and community practice-based
patients. Importantly, employment of the "NIH protocol" in this
cohort produced overall five-year renal survival similar to pub-
lished reports. Moreover, the toxicities of this regimen, employed
in diverse clinical settings outside the confines of a rigorous
clinical trial, were not significantly different from reported clinical
trials.
We noted a subset of patients who rapidly progressed to ESRD
during aggressive therapy. This subset is virtually confined to
black patients despite the lack of clinical, laboratory or pathologic
38 30 21 13 9 5:Non-blacks Table 6. Evaluation of the impact of variables on renal survival in
51 37 25 19 13 12:Backs blacks alone
100
Univariate Multivariate
conditional conditional8O risk ratio risk ratioVariable Median (P value) (Pvslue)"60 Female 0.7 (0.61) 0.9 (0.93)
40 Age at biopsy years
36 0.5 (0.23) 0.6 (0.48)
SLE duration months 33 3.0 (0.03) 3.8 (0.05)
Serum creatinine mg/dl 1.3 1.4 (0.51) 0.5 (0.27)
20 1 Uncontrolled hypertension 1.4 (0.58) 0.9 (0.88)
during therapy
_____________
Treated with 2.9 (0.07) 2.3 (0.15)0 __ ___________-—
methylprednisolone
Activity and chronicity 15c 2.0 (0.20) 2.0 (0.32)0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 4.5 5.0
Years from renal biopsy
Fig. 2. Kaplan-Meier survival estimates by race for renal survival out to 5
years. Renal survival estimates for non-blacks was 94.5% at 9 months and
remained at that level for 5 years. Renal survival at nine months for blacks
was 85%, and continued to decline over the 5 year period with renal
survival of 79% at 2 years, 72% at 3 years, 62% at 4 years, and 57% at 5
years. These differences between these renal survival curves between racial
groups were statistically significant (P = 0.007).
a From the Wald chi-square test, testing if the conditional risk ratio is
equivalent to 1.00
"Each variable tested while controlling all the others
C Thevalue for the highest quotile and associated P values are reported.
patient reached ESRD nine months after biopsy and expired four
months later.
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differences between black and non-black patients at the time
treatment was begun. Comparable therapy and blood pressure
control were not adequate to prevent progression to end-stage
renal disease among black compared with non-black patients. We
believe that inclusion of patients in the GDCN registry at the time
of renal biopsy allowed better definition of the early course of
SLE-DPGN. Such patients would be unlikely to be included in
tertiary care center trials with the potential for delayed therapy.
Previous clinical and pathologic series have included subsets of
patients with rapid onset of SLE, often with aggressive nephritis
poorly responsive to immunosuppressive therapy [29—331. In-
creased frequency of black race was not found in a series of lupus
patients with rapidly progressive nephritis requiring dialysis [331•
One prior study has demonstrated a racial difference in renal
response to therapy for severe nephritis. The recent NIH trial
comparing cyclophosphamide regimens with pulse methylpred-
nisolone therapy for lupus nephritis included 28 black patients
among the 56 patients with SLE-DPGN. In this study, black race
was associated with a significant, independent negative influence
on renal survival [40]. It would be of interest to examine the
results of other treatment studies for possible racial differences in
renaJ outcome.
Population-based studies in the United States consistently show
incidence rates of lupus to be approximately three times higher in
blacks compared with whites [5—7]. In populations with significant
black representation, previous reports note increased frequency
of nephritis, renal failure, and mortality among black patients
[9—11, 34—401. Racial differences in socioeconomic status (SES)
accounted for the differences in some [9, 33] but not all patient
series [11, 351. SES in epidemiologic studies typically includes
information about education, income and occupation. However,
studies of SES and outcome in SLE have been limited to medical
insurance status with few exceptions [36, 37]. A recent multicenter
study demonstrates that SES measures and medical insurance
status and income vary over time, complicating interpretation of
the impact of these variables on outcome [41]. Petri et al noted
increased important renal disease independent of SES, but ac-
counted for by hypertension and physician estimate of medical
compliance [36]. In a large, racially balanced population of lupus
patients from the southeastern United States, Studenski et al
suggested black race and SES were independent risk factors for
decreased overall survival [10], although further evaluation of
their cohort's SES by estimate of household income suggested
that race did not independently predict survival [36]. In the same
cohort, Ward and Studenski noted racial differences in nephrosis
and renal failure that were subsumed by group differences in SES
as described by medical insurance status [371. Reveille and
colleagues reported black race as an independent risk factor for
renal involvement and poor overall survival [11]. This finding was
not explained by insurance status as blacks with private insurance
fared no better than those with public or no insurance coverage.
Bakir, Levy and Dunea reported a retrospective analysis of renal
and overall survival in black patients with severe lupus nephritis
revealing strikingly worse outcomes compared with published
trials [39].
We did not design this study anticipating racial differences in
renal outcomes of cyclophosphamide therapy. Therefore, we did
not assess measures of SES such as medical insurance status, level
of education attained, income, or profession. Nor did we estimate
or measure patient compliance or cultural differences in seeking
health care. Patients entered the cohort following referral to a
nephrologist participating in the GDCN and renal biopsy, thus
referral bias may play a role in our results. The SLE-DPGN
cohort reported herein included 57% black patients, slightly
below black representation in the GDCN SLE registry overall.
Presently, blacks comprise 63% of approximately 620 patients
included in the GDCN SLE registry. Although we observed a
cluster of blacks with rapid onset of nephritis and short duration
of SLE, there was no systematic difference in duration of lupus in
the direction expected (shorter in blacks) or in entry serum
creatinine or chronicity indices on biopsy, that might occur if
diagnosis was delayed in blacks due to differences in health care
access or seeking. Black and non-black patients were enrolled
from the same GDCN practices, many providing nephrology care
for geographically distinct referral areas. Presence and control of
hypertension was similar in both racial groups.
Similar to previous studies [5, 10, 35], we found that the black
patients were significantly younger at onset of lupus and nephritis.
Controlling for race, Ward and Studenski noted no independent
influence of age on renal involvement with nephrotic-range
proteinuria or renal failure [42]. Others have attempted to define
prognostic features among American blacks associated with poor
renal and overall survival with inconsistent findings [6—11, 42—45].
We did not find clinical, laboratory, or pathologic differences
between black and non-black patients. Those with the worst
chronicity and activity did poorly, but even this variable did not
explain the difference in outcome by race. Similarly, we identified
no variables predictive of poor renal outcome among blacks
progressing to endstage renal disease versus those maintaining
renal function. We could not examine differences among non-
blacks as too few whites reached a renal endpoint. Among blacks
with SLE-DPGN, further studies are needed to assess possible
predictors of poor outcome. More aggressive therapy may be
necessary for patients with rapidly deteriorating renal function.
The percent of those treated at University of North Carolina
Hospitals progressively decreased over the decade as the GDCN
membership increased. Treatment differences including changes
in general medical practice over time complicate comparison of
renal outcomes of patients treated at the academic center versus
private practice, and thus we did not compare these groups.
Racial differences in renal outcomes not accounted for by
baseline clinical or pathologic differences or important comorbidi-
ties such as hypertension implicate genetic factors. Association of
increased frequencies of HLA-DR-2, -DR3, -DR7 and C4A*QO
[46—53] as well as MHC class ITT polymorphisms have been
reported among black patients with SLE compared with race-
matched controls [52, 53]. An increased frequency of FcyRIIA-
R131 has been noted in black patients with lupus, most strikingly
associated with lupus nephritis [52]. HLA phenotypes were not
determined for patients in this study and therefore genetic
relationships could not be assessed.
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